1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Global Markets for Geothermal Energy

Global Markets for Geothermal Energy

  • March 2016
  • -
  • BCC Research
  • -
  • 208 pages

This BCC Research report provides an up-to-date analysis of recent developments and current trends in the global geothermal energy market. Energy generation forecasts from 2015 through 2020 are given for each major type of the geothermal energy market, with their technologies and regional market.

Use this report to:

Analyze recent developments and current trends in the global geothermal energy market.
Identify significant drivers of revenue growth for the geothermal energy market.
Receive information about types and technologies of geothermal energy used globally.
Learn about the major players in each of the regional geothermal energy markets.

Highlights

The global market for geothermal power generation was nearly $12.2 billion in 2014. The market is expected to reach nearly $20.8 billion by 2020 from $12.9 billion in 2015, increasing at a compound annual growth rate (CAGR) of 10.0% from 2015 to 2020.

Flash steam technology is expected to grow from nearly $6.3 billion in 2015 to $10.8 billion in 2020 at a CAGR of 11.4% for the period 2015-2020.

Dry steam technology will grow from nearly $4.1 billion in 2015 to $5.8 billion in 2020 at a CAGR of 7.4% for the period 2015-2020.

INTRODUCTION


Geothermal energy is the thermal energy that results from the Earth’s internal energy. The global market for geothermal energy has been growing at a rate of 10.9% annually, mainly driven by the electricity transmission and distribution industry responding to mandates to use renewable source of energy. The market is primarily driven by Asia-Pacific, Europe and North America.

In this report geothermal energy market is broadly divided into three types: geothermal power generation, direct heat and geothermal heating pumps. Furthermore, power generation and heating pumps are further segmented based on their technologies. Also, direct heat applications are duly covered in the report.

Globally, the demand for geothermal energy is driven by the increasing demand for electricity, coupled with the handful geothermal resources available in various regions. In addition, favorable legislation and regulations focusing on reduction of CO2 emissions and energy saving are contributing to the growth in the geothermal energy market. In the long-term, increasing demand for renewable energy production and infrastructure development in developing regions along with the increasing demand for power transmission across long distances and increasing investments in geothermal energy generation, smart grids and power infrastructure will be key drivers of this market.

The global market for geothermal energy is growing, primarily driven by Asia-Pacific, Europe and North American regions due to the abundant availability of geothermal energy, coupled with higher demand for electric transmission and distribution with the revival of the global economy and increasing construction and infrastructure activities.

However, in the longer-term, countries with geothermal resources such as Honduras, Armenia, Spain, South Korea, Vietnam, Bolivia, Chile and Djibouti will create huge opportunities for the geothermal energy market.
Mitsubishi Heavy Industries, Sumitomo Corp., Hyundai, GE and Fuji Electric are the major global manufacturers for geothermal power generation accessories.

This report also highlights the supplier landscape with a focus on major companies, which are profiled in detail.

SCOPE OF REPORT

The scope of this report is broad and covers many types and technologies of geothermal energy used globally. The market is broken down into major types, regions, applications and technologies. Energy generation forecasts from 2015 through 2020 are given for each major type of the geothermal energy market, with their technologies
and regional market.

The report also includes a discussion of the major players in each of the regional markets and explains the major global drivers, the current trends, major challenges and the regional dynamics of the market. The report concludes with a special focus on the supplier landscape. It includes detailed profiles of the major vendors in the
geothermal energy industry globally, and discusses the market share of the major players by region.




Table Of Contents

Global Markets for Geothermal Energy
CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
SCOPE OF REPORT 3
INTENDED AUDIENCE 3
RESEARCH METHODOLOGY 4
ANALYST'S CREDENTIALS 5
RELATED BCC RESEARCH REPORTS 5
BCC RESEARCH WEBSITE 5
DISCLAIMER 5
CHAPTER 2 EXECUTIVE SUMMARY 7
SUMMARY TABLE GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 ($
MILLIONS) 8
SUMMARY FIGURE GLOBAL ANTIBIOTICS MARKET BY CLASS, 2015 AND 2020 ($
MILLIONS) 8
CHAPTER 3 MARKET OVERVIEW 10
INTRODUCTION 10
BACTERIA 10
TABLE 1 DIFFERENCES BETWEEN GRAM-NEGATIVE AND GRAM-POSITIVE BACTERIA 11
GRAM-POSITIVE BACTERIA 12
GRAM-NEGATIVE BACTERIA 12
Mycobacterium 13
TABLE 2 CLASSIFICATION OF BACTERIA BY SHAPE 13
BACTERIAL INFECTIONS 14
RESPIRATORY TRACT INFECTIONS 15
Upper Respiratory Tract Infection 15
TABLE 3 PRINCIPLES FOR JUDICIAL USE OF ANTIBIOTICS 15
TABLE 4 INCIDENCE OF UPPER RESPIRATORY TRACT INFECTIONS CAUSED BY
STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%) 17
Lower Respiratory Tract Infection 17
PNEUMONIA 17
TABLE 5 COMMON CAUSATIVE MICROBES OF COMMUNITY AND
HOSPITAL-ACQUIRED PNEUMONIA 18
Community-acquired Pneumonia 18
Hospital-acquired Pneumonia 18
TABLE 6 PREFERRED PHARMACOTHERAPY FOR MICROORGANISMS CAUSING
BACTERIAL PNEUMONIA 19
TABLE 7 INCIDENCE OF COMMUNITY-ACQUIRED PNEUMONIA BY COUNTRY, 2010
(NUMBER/%) 19
TUBERCULOSIS 20
URINARY TRACT INFECTIONS (UTI) 20
TABLE 8 INCIDENCE OF URINARY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS
BY COUNTRY, 2010 (NUMBER/%) 21
SKIN AND SKIN STRUCTURE INFECTIONS 21
TABLE 9 INCIDENCE OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%) 22
Cellulitis and Erysipelas 22
Folliculitis 22
Impetigo and Ecthyma 23
Abscesses 23
Carbuncles and Furuncles 23
GYNECOLOGICAL INFECTIONS 23
TABLE 10 INCIDENCE OF BACTERIAL VAGINOSIS INFECTIONS CAUSED BY
STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%) 24
DEFINITION OF ANTIBIOTIC 24
CLASSIFICATION OF ANTIBIOTICS 24
FIGURE 1 CLASSIFICATION OF ANTIBIOTICS 25
HISTORY OF ANTIBIOTICS AND CURRENT STATUS 25
PRE-ANTIBIOTIC ERA 25
ANTIBIOTIC ERA 26
TABLE 11 U.S. LIFE EXPECTANCY AT BIRTH, 1920-2013 (YEARS) 26
TABLE 12 ANTIBIOTICS: YEAR OF INTRODUCTION, MODE OF ACTION AND TARGET
SPECIES 27
ANTIBIOTIC-RESISTANT BACTERIA 28
MECHANISM OF RESISTANCE 29
TABLE 13 ANTIBIOTICS: MODE OF ACTION 30
Mechanisms of Antimicrobial Resistance 30
TABLE 14 ESTIMATED DEATHS PER YEAR CAUSED BY AMR BY REGION, 2050
(NUMBER) 31
Methods for the Dissemination of Antimicrobial Resistance Genes 32
Resistance to B-Lactam Antibiotics 32
Tetracycline Resistance 32
Chloramphenicol Resistance 32
Aminoglycoside Resistance 33
Quinolone Resistance 33
Macrolide, Lincosamide, and Streptogramin (MLS) Resistance 33
Glycopeptide Resistance 33
Sulfonamides and Trimethoprim Resistance 34
Multidrug Resistance 34
TABLE 15 TYPES OF ANTIBIOTICS AND METHODS OF RESISTANCE 34
TABLE 16 CURRENT AND EMERGING ANTIBIOTIC-RESISTANT BACTERIA 35
EMERGENCE OF POST-ANTIBIOTIC ERA 36
TABLE 17 BIOCHEMICAL MECHANISM OF ANTIBIOTIC RESISTANCE 37
FIGURE 2 CDC LIST OF HIGHLY CONCERNING BACTERIA, ACCORDING TO THREAT
LEVEL 37
TABLE 18 ADDITIONAL COST AND LENGTH OF STAY DUE TO
ANTIBIOTIC-RESISTANT BACTERIA BY REGION 38
Limitation of Antibiotics 39
Some Antibiotics are Active against Only Certain Kinds of
Bacteria 39
Some Bacteria are Virulent and Can Kill Quickly 40
Some Bacteria Grow in Biofilms that cannot be Easily Penetrated
by Antibiotics 40
DRIVERS RESTRAINTS AND OPPORTUNITIES 40
DRIVERS 40
Growth of the Global Pharmaceutical Market Driven by Antibiotics 40
Aging Population Propels the Growth of the Antibiotics Market 41
FIGURE 3 INCREASE IN AGING POPULATION, 2011 AND 2050 41
Public-Private Partnerships Encourage Antibiotic Development 42
Increasing Prevalence of Hospital-Acquired Infections Triggers Market
Growth 42
RESTRAINTS 43
Antibiotic Resistance 43
Declining RandD Investment Poses Long-Term Barrier to Market Growth 44
Genericization of Antibiotics Restrains Market Growth 44
OPPORTUNITIES 44
Market Expansion into Emerging Countries 44
Multidrug-Resistant Pathogens Provide an Opportunity to Develop
Novel Antibacterial Agents 45
BURNING ISSUE 46
New Antibiotic Discovered From Soil 46
MARKET SHARES OF KEY COMPANIES 46
FIGURE 4 GLOBAL MARKET SHARES FOR ANTIBIOTIC COMPANIES, 2014 (%) 46
VALUE CHAIN OF ANTIBIOTICS 48
CHINA IS A BECOMING A CENTER FOR MICROBIAL THREATS 49
REGULATORY ISSUES 50
FDA AND INTERNATIONAL REGULATORY AGENCIES 50
RECENT REGULATORY REFORMS 51
KETEK CASE STUDY 51
KEY TRENDS AFFECTING THE MARKET 52
NEVER EVENTS 52
Impact on the Use of Antibiotics 53
FUNDING FOR NEW ANTIBIOTICS 53
United States 53
Infectious Diseases Society of America 53
NIH Funding 54
Public-Private Partnerships 54
Europe 55
Innovative Medicines Initiative 55
EMERGING DRUGS WITH NOVEL MECHANISMS OF ACTION 56
PharmaSea Project 56
Combination of Different Antibiotics 56
Others 57
CHAPTER 4 ANTIBIOTIC RESEARCH AND DEVELOPMENT 59
REASONS FOR LACK OF INNOVATION IN ANTIBIOTIC RESEARCH 59
FIGURE 5 REASONS FOR LACK OF INNOVATION IN ANTIBIOTIC RESEARCH 60
LOW RETURN ON INVESTMENT 60
STRICT REGULATORY ENVIRONMENT 61
SCIENTIFIC CHALLENGES 62
STRATEGIES TO PROMOTE ANTIBIOTIC RESEARCH 62
FIGURE 6 STRATEGIES TO PROMOTE ANTIBIOTIC RESEARCH 62
PUSH STRATEGIES 63
Increasing Access to Research 63
Increasing the Number of Scientific Personnel 64
Direct Funding of Research 64
Translational Research 66
Tax Incentives 66
Product Development Partnerships 67
PULL STRATEGIES 67
Monetary Awards 67
Advance Market Commitments 68
Legal and Regulatory Initiatives 69
Clinical Trials 69
Accelerated Regulatory Review 70
Intellectual Property Rights Strategies 70
Increasing the Term of IP Protection and Data Exclusivity 71
Wildcard Patent Extension 71
Patent Buyouts 72
Pricing and Reimbursement 72
Other Legal/Regulatory Strategies 72
COMBINED PULL AND PUSH INCENTIVES 73
ORPHAN DRUG STATUS 73
TABLE 19 COMPARISON OF U.S. AND EU ORPHAN DRUG LEGISLATION AND
PROCESS 73
Delinkage of Antibiotics 74
TABLE 20 LIST OF DELINKAGE MODELS 75
TABLE 21 LIST OF HYBRID MODELS 77
CHAPTER 5 ANTIBIOTICS MARKET BY TYPE 80
MARKET SIZE ESTIMATION 80
MARKET SHARE ESTIMATION 80
GLOBAL ANTIBIOTICS MARKET BY CLASS 81
TABLE 22 GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 ($ MILLIONS) 81
TABLE 23 GLOBAL ANTIBIOTICS MARKET BY REGION, THROUGH 2020 ($ MILLIONS) 81
FIGURE 7 ANTIBIOTICS BY CLASS 81
BETA-LACTAM ANTIBIOTICS 82
TABLE 24 GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY TYPE, THROUGH
2020 ($ MILLIONS) 84
TABLE 25 GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY REGION, THROUGH
2020 ($ MILLIONS) 84
Extended Spectrum Beta-Lactamase 84
Metallo-Beta-Lactamases 85
FIGURE 8 TYPES OF BETA-LACTAM ANTIBIOTICS 85
Penicillins 85
TABLE 26 GLOBAL MARKET FOR PENICILLIN BY REGION, THROUGH 2020 ($
MILLIONS) 86
Types of Penicillin 87
TABLE 27 TYPES OF PENICILLIN BY BRAND NAME AND APPROVAL DATE 88
Cephalosporins 88
Side Effects 89
TABLE 28 GLOBAL MARKET FOR CEPHALOSPORIN BY REGION, THROUGH 2020 ($
MILLIONS) 89
Teflaro Driving the Cephalosporin Market 90
Generations of Cephalosporins 90
TABLE 29 GENERATIONS OF CEPHALOSPORIN 90
First-Generation Cephalosporins 91
TABLE 30 LIST OF FIRST-GENERATION CEPHALOSPORINS 91
Second-Generation Cephalosporins 92
TABLE 31 LIST OF SECOND-GENERATION CEPHALOSPORINS 92
Third-Generation Cephalosporins 92
Antipseudomonal Cephalosporins 93
TABLE 32 LIST OF THIRD-GENERATION CEPHALOSPORINS 93
Fourth-Generation Cephalosporins 94
TABLE 33 LIST OF FOURTH-GENERATION CEPHALOSPORINS 94
Fifth-Generation Cephalosporins 94
TABLE 34 LIST OF FIFTH-GENERATION CEPHALOSPORINS 95
Carbapenems 95
TABLE 35 GLOBAL MARKET FOR CARBAPENEM BY REGION, THROUGH 2020 ($
MILLIONS) 96
TABLE 36 TYPES OF CARBAPENEMS 96
QUINOLONES AND FLUOROQUINOLONES 96
TABLE 37 DEVELOPMENT HISTORY OF FLUOROQUINOLONES 98
TABLE 38 GLOBAL MARKET FOR FLUOROQUINOLONES BY GENERATION, THROUGH
2020 ($ MILLIONS) 98
TABLE 39 GLOBAL MARKET FOR FLUOROQUINOLONES BY REGION, THROUGH 2020
($ MILLIONS) 99
Generations of Quinolones 99
First-Generation Quinolones 99
Second-Generation Fluoroquinolones 99
TABLE 40 GLOBAL MARKET FOR SECOND-GENERATION FLUOROQUINOLONES BY
REGION, THROUGH 2020 ($ MILLIONS) 100
Third-Generation Fluoroquinolones 100
TABLE 41 GLOBAL MARKET FOR THIRD-GENERATION FLUOROQUINOLONES BY
REGION, THROUGH 2020 ($ MILLIONS) 101
Levofloxacin: A Major Driver of the Market for
Third-Generation Fluoroquinolones 101
Fourth-Generation Fluoroquinolones 101
TABLE 42 GLOBAL MARKET FOR OTHER QUINOLONES BY REGION, THROUGH 2020
($ MILLIONS) 102
TABLE 43 TYPES OF QUINOLONES 102
TETRACYCLINE 103
TABLE 44 GLOBAL MARKET FOR TETRACYCLINE BY REGION, THROUGH 2020 ($
MILLIONS) 104
TABLE 45 TYPES OF TETRACYCLINE 104
MACROLIDES 105
TABLE 46 GLOBAL MARKET FOR MACROLIDE BY REGION, THROUGH 2020 ($
MILLIONS) 106
Ketolides 106
Ketek 107
TABLE 47 TYPES OF MACROLIDES/KETOLIDES 107
OTHER ANTIBIOTICS 107
Pseudomonas Aeruginosa 107
TABLE 48 GLOBAL MARKET FOR OTHER ANTIBIOTICS BY REGION, THROUGH 2020
($ MILLIONS) 108
CHAPTER 6 VETERINARY ANTIBIOTICS MARKET 111
INTRODUCTION 111
TABLE 49 DIFFERENCES BETWEEN ANTIBIOTIC USAGE IN ANIMALS AND HUMANS 111
TABLE 50 GLOBAL MARKET FOR VETERINARY ANTIBIOTICS BY APPLICATION,
THROUGH 2020 ($ MILLIONS) 112
VETERINARY APPLICATIONS 112
FEED APPLICATION 112
FDA to Phase out Antibiotics from Food Production 113
THERAPEUTIC APPLICATIONS 114
TABLE 51 GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY TYPE,
THROUGH 2020 ($ MILLIONS) 114
TABLE 52 GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY
ANIMAL TYPE, THROUGH 2020 ($ MILLIONS) 115
OTHER APPLICATIONS 115
CHAPTER 7 COMPANY PROFILES 118
ASTRAZENECA 118
FINANCIALS 118
TABLE 53 ASTRAZENECA REVENUES AND R andD EXPENDITURES, 2012-2014 ($
MILLIONS/%) 118
DEVELOPMENTS 119
TABLE 54 ASTRAZENECA DEVELOPMENTS 119
BAYER HEALTHCARE AG 120
FINANCIALS 120
TABLE 55 BAYER REVENUES AND R andD EXPENDITURES, 2012-2014 ($ MILLIONS/%) 120
DEVELOPMENTS 120
CUBIST PHARMACEUTICALS 120
DEVELOPMENTS 121
TABLE 56 CUBIST PHARMACEUTICAL DEVELOPMENTS 121
GLAXOSMITHKLINE 122
FINANCIALS 122
TABLE 57 GSK REVENUES AND R and D EXPENDITURES, 2012-2014 ($ MILLIONS/%) 122
DEVELOPMENTS 123
TABLE 58 GSK DEVELOPMENTS 123
JOHNSON and JOHNSON 124
FINANCIALS 124
TABLE 59 JOHNSON and JOHNSON REVENUES AND R andD EXPENDITURES, 2012-2014
($ MILLIONS/%) 124
DEVELOPMENTS 125
TABLE 60 JOHNSON and JOHNSON DEVELOPMENTS 125
MERCK and CO. 125
FINANCIALS 125
TABLE 61 MERCK and CO. REVENUES AND R andD EXPENDITURES, 2012-2014 ($
MILLIONS/%) 126
DEVELOPMENTS 126
TABLE 62 MERCK and CO.DEVELOPMENTS 126
PFIZER 126
FINANCIALS 127
TABLE 63 PFIZER REVENUES AND R andD EXPENDITURES, 2012-2014 ($ MILLIONS/%) 127
DEVELOPMENTS 127
TABLE 64 PFIZER DEVELOPMENTS 127
RECENT MERGERS AND ACQUISITIONS 128
TABLE 65 LIST OF OTHER COMPANIES IN THE ANTIBIOTICS MARKET 129
CHAPTER 8 CLINICAL TRIALS ON ANTIBIOTICS 133
FIGURE 9 ANTIBIOTICS IN PHASES I-III CLINICAL TRIALS, 2015 (%) 134
TABLE 66 ANTIBIOTIC COMPOUNDS IN PHASE III CLINICAL TRIALS, 2015 135
ANTIBIOTICS IN PHASE II CLINICAL TRIALS 136
TABLE 67 ANTIBIOTIC COMPOUNDS IN PHASE II CLINICAL TRIALS, 2015 136
ANTIBIOTICS IN PHASE I CLINICAL TRIALS 137
TABLE 68 ANTIBIOTIC COMPOUNDS IN PHASE I CLINICAL TRIALS, 2015 138
TABLE 69 NATURAL PRODUCTS IN CLINICAL TRIALS FOR ANTIBIOTIC ACTIVITY
THAT REPRESENT NEW CHEMICAL CLASSES, 2015 139
CHAPTER 9 OVERVIEW OF BACTERIA TYPES 142
DISEASE ORGANISMS, DIAGNOSTICS, CLINICAL MANIFESTATIONS AND
TREATMENTS 142
TABLE 70 LIST OF GRAM-POSITIVE BACTERIA 142
TABLE 71 LIST OF GRAM-NEGATIVE BACTERIA 146
TABLE 72 LIST OF GRAM-NEGATIVE COCCI 151
TABLE 73 LIST OF GRAM-NEGATIVE RODS RELATED TO RESPIRATORY TRACT
INFECTIONS 153
TABLE 74 LIST OF GRAM-NEGATIVE RODS RELATED TO THE ENTERIC TRACT 155
TABLE 75 LIST OF GRAM-NEGATIVE SPIROCHETES 159
TABLE 76 LIST OF GRAM-NEGATIVE OBLIGATE INTRACELLULAR PARASITES 161
TABLE 77 LIST OF MISCELLANEOUS BACTERIA 163
CHAPTER 10 LIST OF ACRONYMS 166
LIST OF ACRONYMS 166

LIST OF TABLES

SUMMARY TABLE GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 ($
MILLIONS) 8
TABLE 1 DIFFERENCES BETWEEN GRAM-NEGATIVE AND GRAM-POSITIVE BACTERIA 11
TABLE 2 CLASSIFICATION OF BACTERIA BY SHAPE 13
TABLE 3 PRINCIPLES FOR JUDICIAL USE OF ANTIBIOTICS 15
TABLE 4 INCIDENCE OF UPPER RESPIRATORY TRACT INFECTIONS CAUSED BY
STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%) 17
TABLE 5 COMMON CAUSATIVE MICROBES OF COMMUNITY AND HOSPITAL-ACQUIRED
PNEUMONIA 18
TABLE 6 PREFERRED PHARMACOTHERAPY FOR MICROORGANISMS CAUSING
BACTERIAL PNEUMONIA 19
TABLE 7 INCIDENCE OF COMMUNITY-ACQUIRED PNEUMONIA BY COUNTRY, 2010
(NUMBER/%) 19
TABLE 8 INCIDENCE OF URINARY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS
BY COUNTRY, 2010 (NUMBER/%) 21
TABLE 9 INCIDENCE OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%) 22
TABLE 10 INCIDENCE OF BACTERIAL VAGINOSIS INFECTIONS CAUSED BY
STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%) 24
TABLE 11 U.S. LIFE EXPECTANCY AT BIRTH, 1920-2013 (YEARS) 26
TABLE 12 ANTIBIOTICS: YEAR OF INTRODUCTION, MODE OF ACTION AND TARGET
SPECIES 27
TABLE 13 ANTIBIOTICS: MODE OF ACTION 30
TABLE 14 ESTIMATED DEATHS PER YEAR CAUSED BY AMR BY REGION, 2050
(NUMBER) 31
TABLE 15 TYPES OF ANTIBIOTICS AND METHODS OF RESISTANCE 34
TABLE 16 CURRENT AND EMERGING ANTIBIOTIC-RESISTANT BACTERIA 35
TABLE 17 BIOCHEMICAL MECHANISM OF ANTIBIOTIC RESISTANCE 37
TABLE 18 ADDITIONAL COST AND LENGTH OF STAY DUE TO ANTIBIOTIC-RESISTANT
BACTERIA BY REGION 38
TABLE 19 COMPARISON OF U.S. AND EU ORPHAN DRUG LEGISLATION AND PROCESS 73
TABLE 20 LIST OF DELINKAGE MODELS 75
TABLE 21 LIST OF HYBRID MODELS 77
TABLE 22 GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 ($ MILLIONS) 81
TABLE 23 GLOBAL ANTIBIOTICS MARKET BY REGION, THROUGH 2020 ($ MILLIONS) 81
TABLE 24 GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY TYPE, THROUGH
2020 ($ MILLIONS) 84
TABLE 25 GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY REGION, THROUGH
2020 ($ MILLIONS) 84
TABLE 26 GLOBAL MARKET FOR PENICILLIN BY REGION, THROUGH 2020 ($
MILLIONS) 86
TABLE 27 TYPES OF PENICILLIN BY BRAND NAME AND APPROVAL DATE 88
TABLE 28 GLOBAL MARKET FOR CEPHALOSPORIN BY REGION, THROUGH 2020 ($
MILLIONS) 89
TABLE 29 GENERATIONS OF CEPHALOSPORIN 90
TABLE 30 LIST OF FIRST-GENERATION CEPHALOSPORINS 91
TABLE 31 LIST OF SECOND-GENERATION CEPHALOSPORINS 92
TABLE 32 LIST OF THIRD-GENERATION CEPHALOSPORINS 93
TABLE 33 LIST OF FOURTH-GENERATION CEPHALOSPORINS 94
TABLE 34 LIST OF FIFTH-GENERATION CEPHALOSPORINS 95
TABLE 35 GLOBAL MARKET FOR CARBAPENEM BY REGION, THROUGH 2020 ($
MILLIONS) 96
TABLE 36 TYPES OF CARBAPENEMS 96
TABLE 37 DEVELOPMENT HISTORY OF FLUOROQUINOLONES 98
TABLE 38 GLOBAL MARKET FOR FLUOROQUINOLONES BY GENERATION, THROUGH
2020 ($ MILLIONS) 98
TABLE 39 GLOBAL MARKET FOR FLUOROQUINOLONES BY REGION, THROUGH 2020
($ MILLIONS) 99
TABLE 40 GLOBAL MARKET FOR SECOND-GENERATION FLUOROQUINOLONES BY
REGION, THROUGH 2020 ($ MILLIONS) 100
TABLE 41 GLOBAL MARKET FOR THIRD-GENERATION FLUOROQUINOLONES BY
REGION, THROUGH 2020 ($ MILLIONS) 101
TABLE 42 GLOBAL MARKET FOR OTHER QUINOLONES BY REGION, THROUGH 2020
($ MILLIONS) 102
TABLE 43 TYPES OF QUINOLONES 102
TABLE 44 GLOBAL MARKET FOR TETRACYCLINE BY REGION, THROUGH 2020 ($
MILLIONS) 104
TABLE 45 TYPES OF TETRACYCLINE 104
TABLE 46 GLOBAL MARKET FOR MACROLIDE BY REGION, THROUGH 2020 ($
MILLIONS) 106
TABLE 47 TYPES OF MACROLIDES/KETOLIDES 107
TABLE 48 GLOBAL MARKET FOR OTHER ANTIBIOTICS BY REGION, THROUGH 2020 ($
MILLIONS) 108
TABLE 49 DIFFERENCES BETWEEN ANTIBIOTIC USAGE IN ANIMALS AND HUMANS 111
TABLE 50 GLOBAL MARKET FOR VETERINARY ANTIBIOTICS BY APPLICATION,
THROUGH 2020 ($ MILLIONS) 112
TABLE 51 GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY TYPE,
THROUGH 2020 ($ MILLIONS) 114
TABLE 52 GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY ANIMAL
TYPE, THROUGH 2020 ($ MILLIONS) 115
TABLE 53 ASTRAZENECA REVENUES AND R andD EXPENDITURES, 2012-2014 ($
MILLIONS/%) 118
TABLE 54 ASTRAZENECA DEVELOPMENTS 119
TABLE 55 BAYER REVENUES AND R andD EXPENDITURES, 2012-2014 ($ MILLIONS/%) 120
TABLE 56 CUBIST PHARMACEUTICAL DEVELOPMENTS 121
TABLE 57 GSK REVENUES AND R and D EXPENDITURES, 2012-2014 ($ MILLIONS/%) 122
TABLE 58 GSK DEVELOPMENTS 123
TABLE 59 JOHNSON and JOHNSON REVENUES AND R andD EXPENDITURES, 2012-2014
($ MILLIONS/%) 124
TABLE 60 JOHNSON and JOHNSON DEVELOPMENTS 125
TABLE 61 MERCK and CO. REVENUES AND R andD EXPENDITURES, 2012-2014 ($
MILLIONS/%) 126
TABLE 62 MERCK and CO.DEVELOPMENTS 126
TABLE 63 PFIZER REVENUES AND R andD EXPENDITURES, 2012-2014 ($ MILLIONS/%) 127
TABLE 64 PFIZER DEVELOPMENTS 127
TABLE 65 LIST OF OTHER COMPANIES IN THE ANTIBIOTICS MARKET 129
TABLE 66 ANTIBIOTIC COMPOUNDS IN PHASE III CLINICAL TRIALS, 2015 135
TABLE 67 ANTIBIOTIC COMPOUNDS IN PHASE II CLINICAL TRIALS, 2015 136
TABLE 68 ANTIBIOTIC COMPOUNDS IN PHASE I CLINICAL TRIALS, 2015 138
PHM025D - Antibiotics: Technologies and Global Markets
TABLE 69 NATURAL PRODUCTS IN CLINICAL TRIALS FOR ANTIBIOTIC ACTIVITY THAT
REPRESENT NEW CHEMICAL CLASSES, 2015 139
TABLE 70 LIST OF GRAM-POSITIVE BACTERIA 142
TABLE 71 LIST OF GRAM-NEGATIVE BACTERIA 146
TABLE 72 LIST OF GRAM-NEGATIVE COCCI 151
TABLE 73 LIST OF GRAM-NEGATIVE RODS RELATED TO RESPIRATORY TRACT
INFECTIONS 153
TABLE 74 LIST OF GRAM-NEGATIVE RODS RELATED TO THE ENTERIC TRACT 155
TABLE 75 LIST OF GRAM-NEGATIVE SPIROCHETES 159
TABLE 76 LIST OF GRAM-NEGATIVE OBLIGATE INTRACELLULAR PARASITES 161
TABLE 77 LIST OF MISCELLANEOUS BACTERIA 163

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Animal Antibiotics and Antimicrobials Market by Product, Mode of Delivery, Animal - Global Forecast to 2021

Animal Antibiotics and Antimicrobials Market by Product, Mode of Delivery, Animal - Global Forecast to 2021

  • $ 5650
  • Industry report
  • December 2016
  • by MarketsandMarkets

The global animal antibiotics and antimicrobials market is estimated to grow at a CAGR of 4.6% from 2016 to 2021, to reach USD 4.73 billion by 2021 from USD 3.77 billion in 2016. The growth of this market ...

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

  • $ 4995
  • Industry report
  • January 2017
  • by GBI Research

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance Summary The antibacterial drug market covers ...

Methicillin-resistant Staphylococcus aureus (MRSA) - Market Insights, Epidemiology and Market Forecast-2023

Methicillin-resistant Staphylococcus aureus (MRSA) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s Methicillin-resistant Staphylococcus aureus (MRSA) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the ...

Acetic Acid Markets In China

January 2017 $ 4000

Download Unlimited Documents from Trusted Public Sources

Anti-Infective and Therapy Market

  • March 2017
    5 pages
  • Anti-Infective  

    Therapy  

View report >

Global Therapy and Anti-Infective Market

  • March 2017
    6 pages
  • Therapy  

    Anti-Infective  

  • World  

View report >

Pharmaceutical Markets in India

  • March 2017
    21 pages
  • Pharmaceutical  

    Antidiabetics  

  • India  

View report >

Related Market Segments :

Anti-Infective

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.